DK0610446T3 - Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose - Google Patents

Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose

Info

Publication number
DK0610446T3
DK0610446T3 DK93908754T DK93908754T DK0610446T3 DK 0610446 T3 DK0610446 T3 DK 0610446T3 DK 93908754 T DK93908754 T DK 93908754T DK 93908754 T DK93908754 T DK 93908754T DK 0610446 T3 DK0610446 T3 DK 0610446T3
Authority
DK
Denmark
Prior art keywords
mbp
residues
synthetic peptide
cerebrospinal fluid
basic protein
Prior art date
Application number
DK93908754T
Other languages
Danish (da)
English (en)
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of DK0610446T3 publication Critical patent/DK0610446T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93908754T 1991-10-22 1992-10-15 Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose DK0610446T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002053799A CA2053799C (fr) 1991-10-22 1991-10-22 Specificite pour les peptides synthetiques de la proteine basique anti-myeline presente dans le liquide cephalorachidien de patients atteints de la sclerose en plaques
PCT/CA1992/000448 WO1993008212A1 (fr) 1991-10-22 1992-10-15 Specificite de peptides synthetiques de proteines de base anti-myeline provenant du liquide cephalo-rachidien d'un individu souffrant de sclerose multiple

Publications (1)

Publication Number Publication Date
DK0610446T3 true DK0610446T3 (da) 2003-07-14

Family

ID=4148603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93908754T DK0610446T3 (da) 1991-10-22 1992-10-15 Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose

Country Status (12)

Country Link
EP (1) EP0610446B1 (fr)
AT (1) ATE236193T1 (fr)
AU (1) AU2750092A (fr)
CA (1) CA2053799C (fr)
DE (1) DE69232987T2 (fr)
DK (1) DK0610446T3 (fr)
ES (1) ES2196007T3 (fr)
FI (1) FI111050B (fr)
NO (1) NO310513B1 (fr)
NZ (1) NZ244807A (fr)
RU (1) RU2121850C1 (fr)
WO (1) WO1993008212A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
ATE213499T1 (de) 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A2 (fr) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
CA2494338C (fr) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Specificite des peptides de la proteine basique anti-myeline et administration de ces peptides aux patients atteints de sclerose en plaques
WO2005009455A1 (fr) * 2003-07-29 2005-02-03 Terentiev Alexandr Alexandrovi Composition de peptides presentant une propriete immunoregulatrice
KR20120103591A (ko) 2009-10-12 2012-09-19 라이프바이오 라보라토리즈 엘엘씨 다발성 경화증 치료용 조성물
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
WO2024094562A1 (fr) * 2022-11-01 2024-05-10 Universität Zürich Nouveaux peptides mbp et leur utilisation dans le traitement de la sclérose en plaques

Also Published As

Publication number Publication date
CA2053799A1 (fr) 1993-04-23
ATE236193T1 (de) 2003-04-15
EP0610446A1 (fr) 1994-08-17
NO310513B1 (no) 2001-07-16
CA2053799C (fr) 2002-03-12
AU2750092A (en) 1993-05-21
RU94027578A (ru) 1996-10-20
WO1993008212A1 (fr) 1993-04-29
DE69232987D1 (de) 2003-05-08
FI941860A (fi) 1994-04-21
DE69232987T2 (de) 2004-01-29
RU2121850C1 (ru) 1998-11-20
FI941860A0 (fi) 1994-04-21
ES2196007T3 (es) 2003-12-16
NO941415D0 (no) 1994-04-19
FI111050B (fi) 2003-05-30
NZ244807A (en) 1997-08-22
NO941415L (fr) 1994-06-22
EP0610446B1 (fr) 2003-04-02

Similar Documents

Publication Publication Date Title
DK0610446T3 (da) Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
DK0789709T3 (da) Peptidspecificitet af anti-myelin basisprotein og administrationen af myelin basisproteinpeptider til dissemineret sklerose patienter
IL116559A0 (en) Chimeric proteins
ATE356140T1 (de) Gd3 mimetische peptide
CY1107445T1 (el) Θραυσματα πεπτιδιου βασικης πρωτεϊνης της μυελινης, οι φαρμακευτικες τους συνθεσεις και η χρηση τους στη θεραπεια της σκληρυνσης κατα πλακας
NZ508812A (en) Peptides for the prevention or treatment of HIV
ATE315646T1 (de) Leukocyten-aktivierender faktor
KR970074790A (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients